Funding News Edition: January 08, 2020 See more articles in this edition
Apply for grant funds to advance research and development of rapid point-of-care diagnostics for hepatitis C virus (HCV) detection and treatment through a new Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics issued by NIAID and the National Institute of Biomedical Imaging and Bioengineering.
The NOSI encourages new applications for translational research and advancement of rapid point-of-care diagnostics that test for active viremic HCV infections. To improve accessibility to diagnostic tests for those infected, you will help develop a diagnostic that is:
One-step HCV infection testing that uses a point-of-care assay would allow patients to receive their result during their visit and allows for rapid care planning and management. We encourage applicants to consult Optimising Diagnosis of Viraemic Hepatitis C Infection: The Development of a Target Product Profile for additional preferred assay qualities and characteristics.
Your application must include proof-of-concept data for the proposed diagnostic platform or technology, have the ultimate goal of detecting an active HCV in human clinical samples, and must not propose serological assays that solely detect antibodies against HCV.
How To Apply
Instead of applying for NOSIs through a grant application link in the NIH Guide notice as you would for a funding opportunity announcement (FOA), you must apply through the relevant FOAs listed in the NOSI.
Choose the FOA that is most appropriate for your research scope and organization type. Follow the FOA’s due dates and other administrative requirements.
Note: For funding consideration, be sure to identify the relevant NOSI in your application. Include “NOT-AI-20-013” (without quotation marks) in the Agency Routing Identifier field box (box 4B) of the SF 424 R&R form.
The NOSI is open for due dates from February 5, 2020, through January 8, 2023.
Direct all NIAID-related inquiries to Dr. Sara Woodson, our scientific contact for the NOSI.